ELPEN Pharmaceutical Co. Inc. S.A. Krka d.d., Novo mesto TAD Pharma GmbH

Poland

All drugs from this manufacturer

  • ELTROMBOPAG KRKA

    The medicine is used to increase the number of platelets in the blood. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (after previous treatment with other methods) and in adults with hepatitis C virus infection who have a low platelet count.

    Dosage form: tablets, film-coated

    Active substance Dosage
    eltrombopag 25 mg

    ATC: B02BX05

  • The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (after failure of other methods) and in adults with a low platelet count caused by hepatitis C virus infection.

    Dosage form: tablets, film-coated

    Active substance Dosage
    eltrombopag 50 mg

    ATC: B02BX05

  • The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (after failure of other methods) and in adults with hepatitis C who have experienced a low platelet count during interferon treatment.

    Dosage form: tablets, film-coated

    Active substance Dosage
    eltrombopag 75 mg

    ATC: B02BX05